

Dear EML Secretariat,

On behalf of [EHMA](#), the leading non-profit umbrella organization of 34 patient associations for Migraine, Cluster Headache, Trigeminal Neuralgia and other headache diseases, dedicated to supporting individuals with migraine and other headaches.

We have read with extreme interest the applications

[A.10 eletriptan naproxen, migraine

A.13 fremanezumab, high frequency and chronic migraine

I.2 amitriptyline - migraine prophylaxis

I.3 bisoprolol - migraine prophylaxis

I.7 Ibuprofen - acute migraine treatment

I.10 Prednisolone, sumatriptan and verapamil - cluster headache]

I write in support of such applications because they address an important need in the general population.


Migraine and cluster headache are highly disabling chronic conditions, underdiagnosed and undertreated.

The addition of more effective drugs for their management is an important step toward better care in many countries.

Our organization is committed to supporting this initiative and is available to provide any further information or assistance. We look forward to the positive impact this development will have on the global health landscape.

Sincerely,

Elena Ruiz de la Torre, Executive Director.
EMHA – European Migraine and Headache Alliance

A handwritten signature in black ink, reading "Elena Ruiz de la Torre", enclosed within a large, loopy oval shape.